ROS1 and non-small cell lung carcinoma: In addition, in a study of patients with ROS1 fusion-positive advanced non-small cell lung cancer (NSCLC) with brain metastases, the final remission rate of intracranial lesions after treatment with entrectinib was 79.2% [83], suggesting that entrectinib is highly likely to cross the blood–brain barrier, which may also be beneficial for treating ATC with brain metastases.